- Home
- SLE vs APVO Comparison
SLE vs APVO Comparison
Compare SLE & APVO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SLE
- APVO
- Stock Information
- Founded
- SLE 2014
- APVO 2016
- Country
- SLE United States
- APVO United States
- Employees
- SLE N/A
- APVO N/A
- Industry
- SLE Services-Misc. Amusement & Recreation
- APVO Biotechnology: Pharmaceutical Preparations
- Sector
- SLE Consumer Discretionary
- APVO Health Care
- Exchange
- SLE Nasdaq
- APVO Nasdaq
- Market Cap
- SLE 6.5M
- APVO 4.1M
- IPO Year
- SLE 2019
- APVO N/A
- Fundamental
- Price
- SLE $5.16
- APVO $3.04
- Analyst Decision
- SLE Strong Buy
- APVO Strong Buy
- Analyst Count
- SLE 2
- APVO 1
- Target Price
- SLE $100.00
- APVO $5,920.00
- AVG Volume (30 Days)
- SLE 161.0K
- APVO 6.7M
- Earning Date
- SLE 08-13-2025
- APVO 08-07-2025
- Dividend Yield
- SLE N/A
- APVO N/A
- EPS Growth
- SLE N/A
- APVO N/A
- EPS
- SLE N/A
- APVO N/A
- Revenue
- SLE $14,691,000.00
- APVO N/A
- Revenue This Year
- SLE N/A
- APVO N/A
- Revenue Next Year
- SLE $30.36
- APVO N/A
- P/E Ratio
- SLE N/A
- APVO N/A
- Revenue Growth
- SLE N/A
- APVO N/A
- 52 Week Low
- SLE $3.91
- APVO $2.81
- 52 Week High
- SLE $65.60
- APVO $485.37
- Technical
- Relative Strength Index (RSI)
- SLE 45.49
- APVO 33.93
- Support Level
- SLE $4.26
- APVO $2.90
- Resistance Level
- SLE $5.53
- APVO $3.19
- Average True Range (ATR)
- SLE 0.52
- APVO 1.06
- MACD
- SLE 0.26
- APVO 0.24
- Stochastic Oscillator
- SLE 77.40
- APVO 2.23
About SLE Super League Enterprise Inc.
Super League Enterprise Inc is the rocket ship to the metaverse. It is a creator and publisher of content experiences and media solutions across the globe's immersive platforms. Its solutions provide incomparable access to massive audiences that gather in immersive digital spaces to socialize, play, explore, collaborate, shop, learn, and create. The company offers a complete range of development, distribution, monetization, and optimization capabilities designed to engage users through dynamic, energized programs. It generates revenue from advertising, including immersive game world and experience publishing and in-game media products, direct-to-consumer offers, including in-game items, e-commerce, game passes and ticketing and digital collectibles, and content and technology.
About APVO Aptevo Therapeutics Inc.
Aptevo Therapeutics Inc is a clinical-stage research and development biotechnology company focused on developing novel immunotherapeutic candidates for the treatment of different forms of cancer. Its clinical candidates are; ALG.APV-527, which targets co-stimulatory receptors and tumor antigens, and CD3xCD123, which is being developed as a potential treatment of frontline acute myelogenous leukemia. The company's preclinical candidates, APVO711, APVO0442, and APVO603, are being developed using the ADAPTIR modular protein technology platform. The company's versatile and robust ADAPTIR and ADAPTIR-FLEX platforms are designed to generate monospecific, bispecific, and multi-specific antibody candidates that are capable of enhancing the human immune system against cancer cells.